^
Association details:
| Biomarker: | NPM1-ALK fusion |
|---|---|
| Cancer: | Non-Hodgkin’s Lymphoma |
| Drug: | Xospata (gilteritinib) (Multi-tyrosine kinase inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Gilteritinib overcomes lorlatinib resistance in ALK-rearranged cancer
Published date:
02/24/2021
Excerpt:
...gilteritinib exhibited efficacy against NPM-ALK fusion oncogene-positive KARPAS 299 cells, a non-Hodgkin’s Ki-positive large cell lymphoma cell line...
DOI:
10.1038/s41467-021-21396-w
